Will Social Security recipients need a PIN from August 18? Here's all details
Tired of too many ads?
Remove Ads
SSA Faces Pushback Over PIN Requirement
Experts Warned of Accessibility Issues
Tired of too many ads?
Remove Ads
AARP Urges Reconsideration
SSA Clarifies PIN Use is Optional
Focus on Fraud Prevention Continues
Tired of too many ads?
Remove Ads
Direct Deposit Mandate Begins in September
Political Tensions and Future Cuts
FAQs
A recent policy reversal by the Social Security Administration has clarified that a planned requirement for a personal identification number (PIN) will now be optional. The change comes after criticism from advocacy groups and experts who raised concerns about the burden on seniors and people with disabilities.The Social Security Administration (SSA) initially announced that starting August 18, Social Security recipients would need to either go online or visit a field office to obtain a PIN. The PIN would have been necessary to complete tasks like address updates, tax form requests, and claim status checks.According to a regulatory filing, the policy aimed to enhance security for recipients. However, the SSA estimated that the change would result in about 3.4 million additional field office visits per year.Kathleen Romig from the Center on Budget and Policy Priorities (CBPP) raised concerns about the new requirement. She noted that many Social Security recipients live in rural areas or face mobility issues. She argued that the change would cause significant inconvenience and pointed to the lack of public consultation.The CBPP also highlighted that most recipients live at least one hour away from their nearest SSA office. The group questioned whether the SSA had provided sufficient evidence of fraud that would justify the policy.The American Association of Retired Persons (AARP) sent a letter to SSA Commissioner Frank Bisignano. The letter pointed out that older Americans and people with disabilities may not have access to a computer or internet connection. This would force them to make in-person visits to SSA offices.AARP emphasized the need for accessible alternatives, especially for those who are unable to travel easily.After the backlash, the SSA clarified that the PIN feature will not be mandatory. A spokesperson stated that the expanded Secure Authentication Project (SAP) feature was always intended to be optional.Those who do not wish to use the PIN or who lack a 'my Social Security' account can continue using existing identity verification methods. The SSA added that the customer experience will remain unchanged for those opting out.The regulatory filing has not yet been updated, but the SSA confirmed it plans to amend it soon to reflect the optional nature of the PIN feature.The PIN requirement was part of broader fraud prevention efforts by the SSA. In spring, the agency launched anti-fraud phone software to detect suspicious activity. Each year, the SSA receives about 4.5 million phone-based claims, with around 70,000 marked as potentially fraudulent.A previous SSA policy proposal aimed to end identity verification over the phone. Had it been implemented, about six million seniors would have needed to visit SSA offices. That plan was also reversed earlier this year.Another major change will take effect on September 30. The U.S. Department of the Treasury will stop issuing paper checks to Social Security recipients. All payments will need to be made through direct deposit or other electronic methods.The directive comes from a White House executive order and is expected to save about $750 million annually. The move also aims to reduce fraud related to mailed checks. Around 1.9 million additional field office visits are expected because of this switch.Recipients must enroll in direct deposit before the deadline to avoid delays in their benefits.SSA Commissioner Frank Bisignano recently responded to criticism from Democratic senators about alleged mismanagement and growing backlogs at the agency. Meanwhile, concerns persist over future Social Security funding, with projections suggesting benefit cuts of more than $18,000 per person if issues are not addressed.No. The SSA confirmed that using the PIN is optional. Recipients can continue to use current methods for identity verification without needing to visit a field office.Recipients who fail to enroll in electronic payments by the deadline may face delays in receiving benefits as paper checks will no longer be issued.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
an hour ago
- Business Standard
Trump admin freezes $584 mn UCLA grants, research projects at risk
The Trump administration has suspended $584 million in federal grants for the University of California, Los Angeles, nearly double the amount that was previously thought, the school's chancellor announced on Wednesday. UCLA is the first public university whose federal grants have been targeted by the administration over allegations of civil rights violations related to antisemitism and affirmative action. The Trump administration has frozen or paused federal funding over similar allegations against private colleges. "If these funds remain suspended, it will be devastating for UCLA and for Americans across the nation," Chancellor Julio Frenk said on Wednesday in a statement, noting the groundbreaking research that has come out of the university. The departments affected rely on funding from the National Science Foundation, the National Institutes of Health and the Department of Energy, Frenk said. The US Department of Education did not immediately respond to an email from The Associated Press requesting comment. The Trump administration recently announced the US Department of Justice's Civil Rights Division found UCLA violated the Equal Protection Clause of the Fourteenth Amendment and Title VI of the Civil Rights Act of 1964 "by acting with deliberate indifference in creating a hostile educational environment for Jewish and Israeli students". The announcement came as UCLA reached a USD 6 million settlement with three Jewish students and a Jewish professor who sued the university, arguing it violated their civil rights by allowing pro-Palestinian protesters in 2024 to block their access to classes and other areas on campus. The university has said that it is committed to campus safety and inclusivity and will continue to implement recommendations. The new UC president, James B Milliken, said in a statement on Wednesday that it has agreed to talks with the administration over the allegations against UCLA. "These cuts do nothing to address antisemitism," Milliken said. "Moreover, the extensive work that UCLA and the entire University of California have taken to combat antisemitism has apparently been ignored." Milliken said the "cuts would be a death knell for innovative work that saves lives, grows our economy, and fortifies our national security. It is in our country's best interest that funding be restored". As part of the lawsuit settlement, UCLA said it will contribute USD 2.3 million to eight organisations that combat antisemitism and support the university's Jewish community. It also has created an Office of Campus and Community Safety, instituting new policies to manage protests on campus. Frenk, whose Jewish father and grandparents fled Nazi Germany to Mexico and whose wife is the daughter of a Holocaust survivor, launched an initiative to combat antisemitism and anti-Israeli bias. Last week, Columbia agreed to pay USD 200 million as part of a settlement to resolve investigations into the government's allegations that the school violated federal antidiscrimination laws. The agreement also restores more than USD 400 million in research grants. The Trump administration plans to use its deal with Columbia as a template for other universities, with financial penalties that are now seen as an expectation.
Mint
6 hours ago
- Mint
UCLA research frozen: $584 million grant cut stuns campus
The Trump administration has frozen $584 million in federal grants for UCLA, more than double earlier estimates, threatening hundreds of research projects. Chancellor Julio Frenk announced the massive cut Wednesday, revealing that agencies like the National Science Foundation (NSF) and National Institutes of Health (NIH) suspended funding over claims of antisemitism on campus. UCLA is the first public university targeted this way, following similar moves against private schools like Harvard and Columbia. Frenk warned the freeze would be "devastating for Americans nationwide," impacting studies on diseases, clean energy, and national security. The freeze affects 800 grants, including life-saving organ transplant research pioneered at UCLA. The cuts followed a U.S. Department of Justice report accusing UCLA of ignoring antisemitism during 2024 pro-Palestinian protests, despite the university recently paying a $6 million settlement to Jewish students over the same encampment. Federal agencies gave conflicting justifications: the NSF cited "misaligned priorities," while the Department of Energy bizarrely claimed UCLA "endangers women" by allowing transgender athletes and uses "illegal affirmative action" in admissions. UC President James Milliken slammed the move, stating: "These cuts do nothing to address antisemitism" and would be a "death knell" for medical and scientific breakthroughs. UCLA has created a safety office and antisemitism task force since the protests. Under pressure, the University of California agreed to negotiate with the Trump administration before a September 2 lawsuit deadline . The talks aim to restore funding, but precedents are worrying: Columbia paid $200 million and Brown University paid $50 million to regain their grants. Over 3,000 UCLA staff attended an emergency town hall Monday, with Vice Chancellor Roger Wakimoto warning that researchers can't even access existing funds for critical work . Frenk, whose family fled Nazi Germany, stressed UCLA's reforms but called the freeze a "cruel manipulation" unrelated to fighting hate . California Governor Gavin Newsom blasted Trump for 'weaponizing Jewish students' pain'. Organ transplant technology keeping lungs "breathing" outside bodies Asteroid-tracking systems guarding Earth from space threats Valley fever treatment research for the deadly disease Faculty warn the freeze could cancel decades of progress, like UCLA's role in creating the internet . With Columbia's settlement as a template, UCLA faces tough choices: pay massive fines or risk permanent cuts. "Every deal made makes it harder for others to resist," warned American Association of University Professors director Mia McIver . As UC negotiates, scientists statewide brace for ripple effects, hoping lifesaving work won't become collateral in a political war .
Economic Times
7 hours ago
- Economic Times
Novo Nordisk CEO warns of layoffs as Wegovy challenge heats up
Synopsis Novo Nordisk warned of ongoing competition from copycat versions of its obesity drug Wegovy and signaled possible layoffs due to slowing sales growth, especially in the U.S. The Danish drugmaker, which lost $95 billion in market value after cutting full-year forecasts, said over one million Americans still use compounded GLP-1 drugs despite a U.S. ban. Reuters Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could face layoffs as it battles rising pressure from main U.S. rival Eli Lilly, the Danish drugmaker warned on Wednesday. Novo, which became Europe's most valuable company worth $650 billion last year on booming sales of Wegovy, is facing a pivotal moment as the medicine loses market share and sees sales growth slow, especially in the United States. It has warned of far slower growth this year - in part due to compounders who have been allowed to make copycat medicines based on the same ingredients as Wegovy due to shortages. Novo cut its full-year sales and profit forecasts last week, wiping $95 billion off its market value since. The shares were down 3.4% at 1350 GMT. The slide is a huge and abrupt turnaround for the firm that has been one of the world's hottest investment stories, which led to a rapid expansion of manufacturing and sales capacity. Now the firm is eyeing potential cost-cutting measures. "We probably won't be able to avoid layoffs," outgoing CEO Lars Fruergaard Jorgensen told Danish broadcaster DR. "When you have to adjust a company, there are some areas where you have to have fewer people, some (areas) where you have to be smaller." He added, though, that any decision on layoffs would be in the hands of the incoming CEO, company veteran Maziar Mike Doustdar, who takes over on Thursday. On a media call, Jorgensen said the market for copycat versions of Wegovy's class of drugs - known as GLP-1 receptor agonists - was of "equal size to our business" and compounded versions of Wegovy were sold at a "much lower price point". In May, the company said it expected many of the roughly one million U.S. patients using compounded GLP-1 drugs to switch to branded treatments after a U.S. Food and Drug Administration ban on compounded copies of Wegovy took effect on May 22, and it expected compounding to wind down in the third quarter. However, finance chief Karsten Munk Knudsen said on Wednesday that more than one million U.S. patients were still using compounded GLP-1s and that Novo's lowered outlook has "not assumed a reduction in compounding" this year. "The obesity market is volatile," Knudsen told analysts when asked under what circumstances the company could see negative growth in the last six months of the year. The low end of Novo's new full-year guidance range would be for "unforeseen events", such as stronger pricing pressure in the U.S. than forecast, he said. The lower end of the range would imply sales around 150 billion Danish crowns ($23 billion) in the second half of 2025, compared with 157 billion in the same period last year. ENCOURAGING PRESCRIPTION DATA Knudsen reiterated that the company was pursuing multiple strategies, including lawsuits against compounding pharmacies, to halt unlawful mass compounding. Jorgensen said the company was encouraged by the latest U.S. prescription data for Wegovy. While the drug was overtaken earlier this year by rival Lilly's Zepbound in terms of U.S. prescriptions, that lead has narrowed in the past month. Second-quarter sales of Wegovy rose by 36% in the U.S. and more than quadrupled in markets outside the U.S. compared to a year ago, Novo said. While Wegovy's U.S. pricing held steady in the quarter, the company expected deeper erosion in the key U.S. market in the second half, due to a greater portion of sales expected from the direct-to-consumer or cash-pay channel, as well as higher rebates and discounts to insurers, Knudsen said. He said Novo was expanding its U.S. direct-to-consumer platform, NovoCare, launched in March, and may need to pursue similar "cash sales" directly to patients, outside of insurance channels, in some markets outside the United States. COST CUTS The company reiterated its full-year earnings expectations on Wednesday after last week's profit warning. Jorgensen said Novo was acting to "ensure efficiencies in our cost base" as the company announced it would terminate eight R&D projects. "There seems to be a larger R&D clean-out than usual, but we do not know if this reflects a strategic re-assessment or just a coincidence," Jefferies analysts said in a note. Investors have questioned whether Novo can stay competitive in the booming weight-loss drug market. Several equity analysts have cut their price targets and recommendation on the stock since last week. Shares in Novo plunged 30% last week - their worst weekly performance in over two decades. Sales rose 18% in the second quarter to 76.86 billion Danish crowns, below analysts' initial expectations.
